The European Commission has approved JENTADUETO for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally ...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2014 -- Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults ...

Boehringer Ingelheim and Lilly Diabetes Alliance present new findings at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting Linagliptin, marketed in the U.S. as Tradjenta ®, ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the clinical trial enrollment of ...

INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--EX US, UK and UAE Medical Media Only. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a 24-week open label arm ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The U.S. Food and Drug ...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination ...

Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced the FDA has approved a supplemental new drug application for Tradjenta tablets for use as add-on therapy to insulin. Tradjenta is a ...

Patients with Type 2 diabetes will soon have a new generic medication. Lupin has received the Food and Drug Administration’s tentative nod for empagliflozin and linagliptin tablets, in dosage ...

Boehringer Ingelheim and Lilly today announced Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood glucose is not ...